Results 61 to 70 of about 19,002 (159)

Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes

Journal of Ophthalmology, Volume 2020, Issue 1, 2020., 2020
Purpose. To assess the safety of biosimilar intravitreal aflibercept (CinnaGen Co., Iran) compared to the reference product (Eylea®; Bayer Schweiz AG, Zurich, Switzerland) in rabbit eyes through functional and histologic studies. Methods. Forty New Zealand albino rabbits were recruited to the study and were divided into four groups to be sacrificed at ...
Alireza Lashay, Hamid Riazi-Esfahani, Hooshang Faghihi, Ahmad Mirshahi, Hassan Khojasteh, Alireza Khodabande, Fahimeh Asadi Amoli, Fariba Ghassemi, Fatemeh Bazvand, Elias Khalili Pour, Nazanin Ebrahimiadib, Ali Torkashvand, Elham Delrish, Miguel Rechichi   +13 more
wiley   +1 more source

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture [PDF]

, 2014
PurposeTo compare the safety profiles of antivascular endothelial growth factor (VEGF) drugs ranibizumab, bevacizumab, aflibercept and ziv-aflibercept on retinal pigment epithelium cells in culture.MethodsHuman retinal pigment epithelium cells (ARPE-19 ...
Kuppermann, Baruch D, del Carpio, Javier Caceres, Kenney, M Cristina, Boyer, David, Malik, Deepika, Tarek, Mohamed, Ramirez, Claudio   +6 more
core   +1 more source

Intraocular Pharmacokinetics and Safety of Subretinal Injection Compared with Intravitreal Application of Conbercept in Vitrectomized Rabbit Eyes

Journal of Ophthalmology, Volume 2020, Issue 1, 2020., 2020
Purpose. To evaluate the ocular pharmacokinetic properties of subretinal conbercept injection in vitrectomized rabbit eyes and to compare them with those by intravitreal injection. Methods. The following groups of New Zealand white rabbits received conbercept injections (0.5 mg/0.05 ml): a subretinal group (subretinal injection in vitrectomized eyes ...
Teng-teng Yao, Xiao-liang Jin, Yuan Yang, Yi-xiao Wang, Ya-li Zhou, Fang-lin He, Zhao-yang Wang, Hamid Ahmadieh   +7 more
wiley   +1 more source

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib

The Oncologist, Volume 25, Issue 1, Page e75-e84, January 2020., 2020
Abstract Background Trifluridine and tipiracil (FTD + TPI) and regorafenib (REG) are approved treatments for the treatment of refractory metastatic colorectal cancer (mCRC). This study assesses adherence and duration of therapy with FTD + TPI versus REG and explores the effect of sequencing on adherence. Materials and Methods Adults diagnosed with mCRC
Anuj K. Patel, Victoria Barghout, Mihran A. Yenikomshian, Guillaume Germain, Philippe Jacques, François Laliberté, Mei S. Duh   +6 more
wiley   +1 more source

Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact

Asia-Pacific Journal of Ophthalmology, 2017
During the past decade, drugs that inhibit the actions of vascular endothelial growth factor (VEGF) have become standard-of-care treatment for a variety of chorioretinal vascular conditions. The off-label, intravitreal use of ziv-aflibercept (Zaltrap) has provided clinicians with an additional cost-effective drug.
Sumit Randhir, Singh, Avantika, Dogra, Michael, Stewart, Taraprasad, Das, Jay, Chhablani   +4 more
openaire   +2 more sources

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. [PDF]

Retina, 2017
Purpose: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration.
de Oliveira Dias JR, de Andrade GC, Kniggendorf VF, Novais EA, Maia A, Meyer C, Watanabe SES, Farah ME, Rodrigues EB.   +8 more
europepmc   +2 more sources

Comparison between ziv-aflibercept and ranibizumab for treatment of diabetic macular edema

Journal of the Egyptian Ophthalmological Society
Aim To evaluate safety and efficacy of ziv-aflibercept in comparison to ranibizumab for the treatment of diabetic macular edema (DME). Patients and methods A total of 84 patients (84 eyes) with DME and central macular thickness (CMT) greater than 350 μ ...
Abdalah S. Nasr, Mahmoud A. Ali, Sherif A. Dabbor, Ahmed F. Gabr   +3 more
doaj   +1 more source

Delivery System and Nanozyme: Nanotechnology‐Based Natural Sources Promise New Approaches in Colorectal Cancer Management

Micro &Nano Letters, Volume 21, Issue 1, January/December 2026.
The paper examines how nanotechnology‐based drug delivery systems using biocompatible nanoparticles function to improve drug pharmacokinetics and deliver medication to tumours while minimising adverse effects. ABSTRACT The worldwide prevalence of colorectal cancer (CRC) makes it a leading cause of death among malignancies.
Ghazala Muteeb, Rawan S. Elsharkawy, Ayda H. El‐Gouhari, Ghannimah Yousef Alghuwainem, Mohammad Aatif, Doaa S. R. Khafaga   +5 more
wiley   +1 more source

Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma

Cancer Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background Uveal melanoma (UM) is the prevailing malignant tumor that develops within the eye in adults, and it has a bleak outlook because of the few treatment choices available and the high likelihood of returning after treatment. Currently, surgical intervention, radiation therapy, and a combination of both modalities are available ...
Alireza Azani, Vahid Ghassemifar, Zahra Mehrdad, Maryam Saberivand, Anahid Bagheripour, Safa Tahmasebi, Hossein Gharedaghi, Malihe Sharafi, Hassan Foroozand, Mohammad Saeed Soleimani Meigoli, Saba Pourali, Arash Salmaninejad, Faeze Ahmadi Beni, Qumars Behfar   +13 more
wiley   +1 more source

Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma

Neoplasia: An International Journal for Oncology Research, 2016
BACKGROUND & AIM: Aflibercept known as ziv-aflibercept in the United States is a soluble decoy receptor of both vascular endothelial growth factor (VEGF) receptor-1 and -2 known to inhibit the binding of VEGF and placental growth factor (PlGF) to VEGF ...
Takuji Torimura, Hideki Iwamoto, Toru Nakamura, Mitsuhiko Abe, Yu Ikezono, Fumitaka Wada, Takahiko Sakaue, Hiroshi Masuda, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano   +11 more
doaj   +1 more source